These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 18054239)
1. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Schäfer S; Saunders L; Eliseeva E; Velena A; Jung M; Schwienhorst A; Strasser A; Dickmanns A; Ficner R; Schlimme S; Sippl W; Verdin E; Jung M Bioorg Med Chem; 2008 Feb; 16(4):2011-33. PubMed ID: 18054239 [TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839 [TBL] [Abstract][Full Text] [Related]
3. Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from alpha-tubulin sequence. Jose B; Okamura S; Kato T; Nishino N; Sumida Y; Yoshida M Bioorg Med Chem; 2004 Mar; 12(6):1351-6. PubMed ID: 15018907 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Dallavalle S; Cincinelli R; Nannei R; Merlini L; Morini G; Penco S; Pisano C; Vesci L; Barbarino M; Zuco V; De Cesare M; Zunino F Eur J Med Chem; 2009 May; 44(5):1900-12. PubMed ID: 19084294 [TBL] [Abstract][Full Text] [Related]
5. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. Mai A; Massa S; Ragno R; Cerbara I; Jesacher F; Loidl P; Brosch G J Med Chem; 2003 Feb; 46(4):512-24. PubMed ID: 12570373 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. Mai A; Massa S; Rotili D; Simeoni S; Ragno R; Botta G; Nebbioso A; Miceli M; Altucci L; Brosch G J Med Chem; 2006 Oct; 49(20):6046-56. PubMed ID: 17004718 [TBL] [Abstract][Full Text] [Related]
7. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Smil DV; Manku S; Chantigny YA; Leit S; Wahhab A; Yan TP; Fournel M; Maroun C; Li Z; Lemieux AM; Nicolescu A; Rahil J; Lefebvre S; Panetta A; Besterman JM; Déziel R Bioorg Med Chem Lett; 2009 Feb; 19(3):688-92. PubMed ID: 19111466 [TBL] [Abstract][Full Text] [Related]
8. Identification of novel isoform-selective inhibitors within class I histone deacetylases. Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486 [TBL] [Abstract][Full Text] [Related]
9. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033 [TBL] [Abstract][Full Text] [Related]
10. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase. Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563 [TBL] [Abstract][Full Text] [Related]
11. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors. Yan C; Xiu Z; Li X; Li S; Hao C; Teng H Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905 [TBL] [Abstract][Full Text] [Related]
12. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations. Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955 [TBL] [Abstract][Full Text] [Related]
13. Structural biasing elements for in-cell histone deacetylase paralog selectivity. Wong JC; Hong R; Schreiber SL J Am Chem Soc; 2003 May; 125(19):5586-7. PubMed ID: 12733869 [TBL] [Abstract][Full Text] [Related]
14. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. Hildmann C; Wegener D; Riester D; Hempel R; Schober A; Merana J; Giurato L; Guccione S; Nielsen TK; Ficner R; Schwienhorst A J Biotechnol; 2006 Jun; 124(1):258-70. PubMed ID: 16567013 [TBL] [Abstract][Full Text] [Related]
15. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways. Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001 [TBL] [Abstract][Full Text] [Related]
19. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities. Ortore G; Di Colo F; Martinelli A J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584 [TBL] [Abstract][Full Text] [Related]
20. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]